The clinical syndrome of heart failure (HF) is associated with a wide spectrum of abnormalities of left ventricular (LV) structure and function, ranging from a normal LV chamber size with a preserved ejection fraction (EF), to severe LV chamber dilatation with a markedly reduced EF. LVEF is considered important with respect to classifying HF patients because of differing patient demographics, prognosis, as well as the response to HF therapies. 1 Current HF guidelines divide the HF population into two separate groups of patients based on their LVEF: those with reduced ejection fraction (HFrEF, EF <40%) and those with preserved ejection fraction (HFpEF, EF >50%). Recently, it has also become clear that the clinical syndrome of HF may develop in patients with LVEFs that range between 40 and 50%. 2 It was originally suggested that patients with a borderline LVEF of between 40 and 50% represented HFpEF patients with isolated diastolic dysfunction whose LVEF declined secondarily to the development of systolic dysfunction. 3, 4 However, the recognition that LVEF The diagnostic criteria for this emerging phenotype includes signs and symptoms of HF, and EF of 40-50%, elevated levels of natriuretic peptides, and either structural heart disease, such as LV hypertrophy and/or left atrial enlargement, or diastolic dysfunction on echocardiography. 9 Of note, the recent ESC guideline update recommends that treatment of HFmrEF patients should follow the HFpEF recommendations, which is that beta-blockers should bot be used for the treatment of HFpEF. Accordingly, a provocative article in this issue of the journal by Cleland and colleagues, 10 in which the authors performed a meta-analysis of individual patient data from 11 clinical trials in order to evaluate the effect of beta-blockers among HFmrEF patients as compared with HFrEF and HFpEF patients, is both timely and of considerable interest.
Cleland et al. demonstrate that beta-blockers reduce cardiovascular mortality among patients with an LVEF of < 50%; and, specifically in the subgroup of LVEF 40-50%, cardiovascular mortality risk was halved [hazard ratio (HR) 0.548, 95% confidence interval (CI) 0.24-0.97]. Notably, 'HFmrEF patients' made up <4% of the entire study population, with the majority of HFmrEF patients having an LVEF of < 43% (median value 40%). Moreover, study patients with an LVEF of 35-39% experienced a 5% improvement in LVEF on average. Under the current ESC guidelines for HFmrEF, a patient with a baseline LVEF of 36% who had a follow-up LVEF of 41% after initiating evidence-based medical or device therapy would be 're-classified' as 'mid-range,' and the guidelines would have recommended discontinuation of the beta-blocker. Before discussing the potential clinical implications of this paper, it is useful to review what we do and not know about patients with a mid-range ejection fraction. 
Heart failure with a mid-range left ventricular ejection fraction
Historically, the classification of HF based on LVEF was an arbitrary decision that arose for a variety of reasons, including (but not limited to) the need to define distinct populations of HF patients with high event rates to enrol in clinical trials (the lower the LVEF the higher the mortality) and the perception that 'systolic dysfunction' was the primary cause of the decline in LVEF in HFrEF, rather than progressive LV remodelling. Today we recognize that patients with HFrEF have profound abnormalities of diastolic function and that patients with HFpEF have abnormalities of systolic function. We also recognize that because LVEF is inversely proportional to LV end-diastolic volume, and that by dichotomizing patients into an LVEF of <40% and an LV mass of > 50% one can reliably identify patients with a dilated left ventricle (eccentric hypertrophy), who respond well to neurohormonal antagonists, and patients with increased LV mass with normal or smaller end-diastolic volumes (concentric hypertrophy), who derive limited benefits from neurohormonal antagoinsts. Thus, LVEF has served as a useful way to identify appropriate management strategies for patients with HF. However, the growing recognition that patients with an LVEF of 40-49% have increased HF hospitalizations and increased cardiovascular death has created consternation, confusion, and intense academic debate because this group of HF patients does not fit nicely into our current HFrEF and HFpEF paradigms.
A simple query of PubMed indicates that we have inadvertently created a number of different nomenclatures for HF patients with an LVEF from 40 to 50%, including: HFimprovedEF Although there is an ongoing debate as to whether HFmrEF represents a distinct subset of patients with HF, if one applies the 'Principal of Parsimony' (Occam's razor) to a contemporary medical practice, the epidemiology of patients with HFmrEF is comprised primarily of patients with HRrEF whose LVEF has recovered following institution of evidence-based medical and device therapies, 14 with a smaller group of patients with HFpEF whose hearts undergo LV dilation with a decline in LVEF (see Figure 1) . We recognize that this interpretation is overly simplistic, and there will undoubtedly be exceptions to this parsimonious approach. However, the important point is that although patients with HFmrEF are a heterogeneous group, a significant proportion of these patients represent HFrEF patients with a recovered LVEF. Given this understanding, the important observation in the report by Cleland and colleagues that beta-blockers decreased cardiovascular mortality in patients with an LVEF of 40-49% is both predictable and reassuring. While the data set used for the meta-analysis did not allow for understanding the trajectory of the LVEF, the patients in this meta-analysis were largely recruited from trials wherein beta-blockers were used to treat HFrEF, which suggests that many of the patients in the LVEF 40-49% range were HFrEF patients whose LVEF had improved. We know that betablockers improve outcomes in patients with HFrEF, and it is reassuring to find that beta-blockers improved outcomes in HFrEF patients with a recovered LVEF in comparison with HFrEF patients with a recovered LVEF who did not receive beta-blockers. The concept of the need to understand the trajectory of the patient's LVEF is also supported by a study by Nadruz et al., who compared outcomes among HF subgroups referred for outpatient cardiopulmonary exercise testing. Despite similar exercise performance metrics, patients with mid-range EF and history of HFrEF with a recovered LVEF had improved overall survival and freedom from transplantation, ventricular assist device, or all-cause mortality compared with HFmrEF without recovery. 15 Hence, the assessment of LVEF is context dependent, and requires prior knowledge about the LVEF trajectory in order to understand patient prognosis fully. While it is premature to comment on whether the study by Cleland et al. will be sufficient to prompt a change in practice guidelines for the management of HFmrEF, this study does highlight the limitations of classifying HF based on LVEF alone and emphasizes the need for more detailed phenotyping in order to individualize targeted medical therapies to improve clinical outcomes in HF.
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